Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of ...

Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of ...

Angelini Ventures and Apollo Health Ventures join existing top-tier investor syndicate

Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline

Angelini Ventures and Apollo Health Ventures join existing top-tier investor syndicate- Follows original $36M Series A raise and brings Series A total to $75M- Proceeds are being used to fund Phase 1b Alzheimer's and DME studies, and bispecific development SACRAMENTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by va…

Therini Bio Raises Additional $39M in Series A Financing

Therini Bio, Inc., a Sacramento, CA-based clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction raised $39m in Series A extension financing. The extension financing included new investors, Angelini Ventures and Apollo Health Ventures, in addition to existing investors SV Health Investors’ Biotech Fund and Dementia Discovery Fund, MRL Ventures Fund, […] The post Th…